Behzat ÖZKAN, Ceyhun DİZDARER, Özlem NALBANTOĞLU, Özge KÖPRÜLÜ, Korcan DEMİR, Selma TUNÇ, Hatice ORTAÇ

Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience

Background/aim: Graves’ disease (GD) is more severe, requires a more complex treatment, and has a lower probability of achievingremission in children than in adults. There is no consensus on the appropriate duration of antithyroid drug (ATD) treatment. Surgicalor radioactive iodine (RAI) treatments are not definitive and generally result in permanent hypothyroidism. This study’s goal wasexamining the effectiveness of ATD treatment in children and adolescents with GD and determining the risk factors of remission andrelapse.Materials and methods: This retrospective study included 45 patients (36 females and 9 males, median age 12.5 years) aged 4–18 whowere diagnosed with GD between 2003 and 2017. All patients initially were treated with an ATD. ATD treatment was discontinued at amean of 23.2 ± 13.2 months (10–37 months).Results: Patients were classified into remission (n = 24) and relapse groups (n = 21). The duration of initial ATD treatment in theremission group was longer (26.91 ± 5.17 months) than in the relapse group (19.09 ± 7.14 months) (P = 0.01). The total ATD treatmentduration was statistically longer in the remission group (42.14 ± 14.35 months) than in the relapse group (26.95 ± 16.13 months) (P =0.03).Conclusion: Long-term initial ATD treatment and long-term total ATD treatment were evaluated as positive parameters for theremission of Graves’ disease in children and adolescents. Our findings showed that the chance of long-term remission increases in directproportion to the initial ATD treatment duration and the total ATD treatment duration.

PDF

___

1. Hung W, Sarlis NJ. Autoimmune and non-autoimmune hyperthyroidism in pediatric patients: a review and personal commentary on management. Pediatr Endocrinol Rev 2004; 2: 21-38.
2. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008; 93: 3817-3826.
3. Rivkees SA. Pediatric Graves’ disease: controversies in management. Horm Res Paediatr 2010; 74: 305-311.
4. Kaguelidou F, Carel JC, Leger J. Graves’ disease in childhood: advances in management with antithyroid drug therapy. Horm Res 2009; 71: 310-317.
5. Bauer AJ. Approach to the pediatric patient with Graves’ disease: when is definitive therapy warranted? J Clin Endocrinol Metab 2011; 96: 580-588.
6. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Lauberg P, McDougall IR, Montori VM, Rivkees SA et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association; American Association of Clinical Endocrinologists. Endocr Pract 2011; 17: 456-520.
7. Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab 2012; 97: 110-119.
8. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 2005; 153: 489-498.
9. Rivkees SA. The treatment of Graves’ disease in children. J Pediatr Endocrinol Metab 2006; 19: 1095-1111.
10. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 2012; 379: 1155-1166.
11. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010; 95: 3260-3267.
12. Rivkees SA. 63 years and 715 days to the “boxed warning”: unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010; 2010: 658267. 13. Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352: 905- 917.
14. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997; 82: 1719-1726.
15. Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics 2008; 122: 481-488.
16. Raees M. The Harriet Lane Handbook. 21st ed. Philadelphia, PA, USA: Elsevier; 2018.
17. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44: 291-303.
18. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45: 13-23.
19. Demir K, Özen S, Konakçı E, Aydın M, Darendeliler F. A comprehensive online calculator for pediatric endocrinologists: ÇEDD Çözüm/TPEDS metrics. J Clin Res Pediatr Endocrinol 2017; 9: 182-184.
20. Aydıner Ö, Karakoç Aydıner E, Akpınar İ, Turan S, Bereket A. Normative data of thyroid volume-ultrasonographic evaluation of 422 subjects aged 0-55 years. J Clin Res Pediatr Endocrinol 2015; 7: 98-101.
21. Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics 2008; 121: 481-488.
22. McCormack S, Mitchell DM, Woo M, Levitsky LL, Ross DS, Misra M. Radioactive iodine for hyperthyroidism in children and adolescents: referral rate and response to treatment. Clin Endocrinol (Oxf) 2009; 71: 884-891.
23. Wong GW, Lai J, Cheng PS. Growth in childhood thyrotoxicosis. Eur J Pediatr 1999; 158: 776-779.
24. Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves’ disease: outcome and treatment. J Pediatr Endocrinol Metab 2003; 16: 1249-1255.
25. Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Suzuki M, Yoshihara A, Ito K et al. Antithyroid drug treatment for Graves’ disease in children: a long-term retrospective study at a single institution. Thyroid 2014; 24: 200-207.
26. Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, Pellegrino D. Factors at onset predictive of lasting re- mission in pediatric patients with Graves’ disease followed for at least three years. J Pediatr Endocrinol Metab 1999; 12: 537-541.
27. Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics 2008; 121: 481-488.
28. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J; French Childhood Graves’ Disease Study Group. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008; 93: 3817-3826.
29. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N; Working Group of the Japan Thyroid Association for the Guideline of the Treatment of Graves’ Disease. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 2007; 92: 2157-2162.
30. Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003; 88: 3474-3481.
31. Laurberg P. Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 2006; 155: 783-786.
32. Shizume K. Long term antithyroid drug therapy for intractable cases of Graves’ disease. Endocrinol Jpn 1978; 25: 377-379.
33. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroid- ism: comparison with radioiodine. Eur J Endocrinol 2005; 152: 695-701.
34. Rivkees SA. Controversies in the management of Graves’ disease in children. J Endocrinol Invest 2006; 39: 1247-1257.
35. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P. Lasting remissions in patients treated for Graves’ hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab 1988; 67: 656-662.
36. Weetman AP, McGregor AM, Hall R. Evidence for an effect of antithyroid drugs on the natural history of Graves’ disease. Clin Endocrinol (Oxf) 1984; 21: 163-172.
37. Kamath C, Adlan MA, Premawardhana LD. The role of thyrotrophin receptor antibody assays in Graves’ disease. J Thyroid Res 2012; 2012: 525936.
38. McLachlan S, Pegg CAS, Atherton MC, Middleton SL, Dickinson A, Clark F, Proctor SJ, Proud G, Rees Smith B. Subpopulation of thyroid auotantibody secreting lymphocytes in Graves’ and Hashimoto thyroid glands. Clin Exp Immunol 1986; 65: 319-328.
39. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev 2010; 20: CD003420.
40. Kourime M, McGowan S, Al Towati M, Ahmed SF, Stewart G, Williamson S, Hunter I. Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling. Arch Dis Child 2018; 103: 637-643.
41. Otsuka F, Noh JY, Chino T, Shimizu T, Mukasa K, Ito K, Taniyama M. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol 2012; 77: 310-315.
42. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21: 593-646.
43. Cassio A, Corrias A, Gualandi S, Tato L, Cesaretti G, Volta C, Weber G, Bona G, Cappa M, Bal M et al. Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol (Oxf) 2006; 64: 53-57.
44. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O’Heir CE, Mitchell ML, Hermos RJ, Waisbren SE et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341: 549-555.